Development of Physiology Based Pharmacokinetic Model to Predict the Drug Interactions of Voriconazole and Venetoclax

Purpose Venetoclax (VEN), an anti-tumor drug that is a substrate of cytochrome P450 3A enzyme (CYP3A4), is used to treat leukemia. Voriconazole (VCZ) is an antifungal medication that inhibits CYP3A4. The goal of this study is to predict the effect of VCZ on VEN exposure. Method Two physiological bas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmaceutical research 2022-08, Vol.39 (8), p.1921-1933
Hauptverfasser:	Dong, Ji, Liu, Shuai-bing, Rasheduzzaman, Jony Md, Huang, Chen-rong, Miao, Li-yan
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Antifungal agents Biochemistry Biomedical and Life Sciences Biomedical Engineering and Bioengineering Biomedicine Bridged Bicyclo Compounds, Heterocyclic - pharmacokinetics Complications and side effects Cytochrome P-450 CYP2C19 - genetics Cytochrome P-450 CYP3A - genetics Cytochrome P-450 CYP3A Inhibitors - pharmacokinetics Cytochrome P450 Dosage Drug dosages Drug interaction Drug Interactions Drug therapy Enzymes Gene polymorphism Humans Leukemia Medical Law Midazolam Models, Biological Original Research Article Pharmacokinetics Pharmacology/Toxicology Pharmacy Physiological aspects Predictions Risk assessment Sulfonamides - pharmacokinetics Tumors Voriconazole Voriconazole - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!